Sector News

Stada CEO ‘happy’ to take 40% pension cut. Sound foreign, U.S. pharma chiefs?

November 14, 2014
Life sciences
Here’s something you don’t see in the U.S.: The chief exec of Germany’s largest independent pharma has agreed to a pension cut worth about 40%–a change he says he was “happy” to consent to.
 
Stada CEO Hartmut Retzlaff’s retirement package will get a €16 slim-down to about €24 million ($29.9 million), Reuters reports. Retzlaff waived the money before taxes as part of a transfer of the package from Stada to an external pension fund, which had been “planned for a long time,” the company’s CFO said on a conference call Thursday.
 
The package for the 21-year helmsman is a far cry from the kind of money long-tenured pharma CEOs can take home in the States. For comparison, former Johnson & Johnson chief Bill Weldon took home a $143 million package when he retired in 2012 after a 40-year stint at the New Jersey drugmaker, with 10 of those years spent in the CEO’s chair.
 
But in Europe, citizens have been known to raise fury over large retirement packages. Just ask former Novartis skipper Daniel Vasella, who saw his 72-million-franc ($74.4 million) goodbye present whittled down to $5.2 million after protests from pay watchdogs. (Swiss voters later passed a referendum giving shareholders the right to reject pay packages for top managers).
 
So while Retzlaff said on the call that he “was happy to” agree to the change in plan–which he didn’t have to do, he noted–he also made the case for the sum he’s still due after retirement.
 
“We managed under my leadership to turn this company, which at the time was already almost a hundred years old, from little better than a rabbit hutch into a reputable MDAX company,” he said, as quoted by Reuters.
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”